entertainment -WSS

entertainment

author：fashion 2025-09-05 13:39:27 - browse：58894

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： NIH trials fail to test meaningful long Covid therapies, experts say

focus

WSS

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Hospitals owned by private equity see complications spike 25%

Carvykti CAR

CRISPR gene editing developments we’re watching in 2024

Three trends to watch in biotech in 2024

Wegovy trial has doctors encouraged over new possibilities

leisure time

entertainment

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why health records don't always know when patients are dead

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Hospitals owned by private equity see complications spike 25%

What does generative AI mean for health care? We asked experts

Can sheer will power keep patients alive in their dying hours?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

At least 13 dead in Texas as scorching temps continue

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

hotspot

Violet CEO on training clinicians to promote more inclusive care

Wegovy’s successful heart trial raises vital question about weight loss

Keeping primary care docs in field isn't impossible, says AAFP CEO

In Spain, a hospital brews its own CAR

Anavex keeps shifting the goalposts in its clinical trials

South Korea throws huge K

focus

focus

focus

hotspot